Welcome to the Biomaterial Systems Group

Our vision is to be home to great researchers in the field of biomaterials, and in particular those that are looking to connect basic research with the clinical application, i.e. developing the biomaterial for its envisaged system, as well as characterizing the material with a specific application in mind.

Our mission is to provide new knowledge and better solutions to medical problems, where the biomaterial or implant design can be the change that is needed.

We conduct interdisciplinary research, with members encompassing material science, mechanical engineering, biology and biomedical engineering. The BioMaterial Systems (BMS) Group is led by Prof. Cecilia Persson. 

Research

When a part of the body stops working, either because of disease or trauma, implants made of biomaterials can be used as replacements. The material choice is not trivial, and depending on what the material is meant to replace, e.g. a piece of bone or a knee joint, there are different requirements on its chemical and mechanical properties. The material needs to be biocompatible, i.e. have the ability to perform with an appropriate host response in a specific situation. This can appear to be a vague definition, but it is a reflection of the importance of putting the material into context in order to evaluate its function. That is, biomaterials need to be evaluated in terms of their function in their system as far as possible, and we put great weight on this in our research.

The BioMaterial Systems Group focuses on the study, development and characterization of new materials and implant designs, mainly for orthopaedic applications, in their systems. Focus lies on injectable materials as well as materials and implant design development through additive manufacturing (3D-printing). We also develop and characterize wear-resistant materials for joint applications. Experimental and computational (e.g. FE) models are used to study the materials and implant/tissue interactions, also inside micro-CTs. Early biocompatibility studies may be done within the group, while when moving further towards the clinical application and/or commercial product, collaborations with e.g. Uppsala University Hospital are employed.